Streptococcus pneumoniae infection future or investigational therapies
|
Streptococcus pneumoniae infection Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Vaccine research
There is currently research into producing vaccines than can be given into the nose rather than by injection.[1] [2] It is believed that this improves vaccine efficacy and also avoids the need for injection.
The development of serotype-specific anticapsular monoclonal antibodies has also been an area of vaccine research in recent years. These antibodies have been shown to prolong survival in a mouse model of pneumococcal infection characterized by a reduction in bacterial loads and a suppression of the host inflammatory response.[3][4]
References
- ↑ Hanniffy SB, Carter AT, Hitchin E, Wellsa JM. (2007). "Mucosal delivery of a Pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection". J Infect Dis. 195: 185–193.
- ↑ Malley R. Lipsitch M, Stack A, Saladino R, Fleisher G, Pelton S, Thompson C, Briles D, Anderson P. (2001). "Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci". Infect Immun. 69: 4870–4873.
- ↑ Burns T, Abadi M, Pirofski L (2005). "Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide". Infect Immun. 73 (8): 4530–8. PMID 16040964.
- ↑ Fabrizio K, Groner A, Boes M, Pirofski L. "A Human Monoclonal IgM Reduces Bacteremia and Inflammation in a Mouse Model of Systemic Pneumococcal Infection". Clin Vaccine Immunol. PMID 17301214.